Back grey_arrow_rt.gif
Amy Patick, Agouron/Nelfinavir Virologist Resurfaces at HCV Biotech
  April 14, 2008
Genelabs Appoints Amy K. Patick, Ph.D. Vice President, Biological Sciences
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genelabs Technologies, Inc. (Nasdaq:GNLB), a biopharmaceutical company focused on discovering novel compounds for hepatitis, announced today that Amy K. Patick, Ph.D. has been appointed Vice President, Biological Sciences.
"We are very pleased to welcome Dr. Patick, an accomplished scientist and recognized leader in antiviral research, to the Genelabs team. As we continue to advance our pipeline of hepatitis C virus (HCV) inhibitors, we will benefit from her expert advice and many years of experience in world-class pharmaceutical companies," said Ronald Griffith, Ph.D. Chief Scientific Officer. "Amy's scientific acumen and extensive antiviral drug development experience span the entire drug development process, from early-stage research, through IND and NDA filings, to successful product launch."
Dr. Patick was recently appointed to the position of President of the International Society of Antiviral Research and most recently has been working with various biotechnology companies as a pharmaceutical and scientific consultant. From 2000 to 2007, she was Senior Director and Head of the Antiviral Biology Therapeutic Area for Pfizer Global Research and Development. Prior to Pfizer, she served in various senior roles at Agouron Pharmaceuticals, Inc. and Bristol-Myers Squibb, specializing in infectious disease drug discovery and clinical development activities. Dr. Patick earned both a Ph.D. and M.S. in medical microbiology from the University of Wisconsin.
Dr. Patick is widely recognized as a leader in scientific and academic communities and has participated in and promoted alliances with pharmaceutical companies, academic institutions, clinical investigators, consultants and public advocacy groups. She is an Editorial Board member for several prestigious antiviral publications, has over 100 published abstracts/presentations and is a co-inventor on more than 20 patents.
"I am very excited to be joining Genelabs at this important and exciting point in its corporate development," said Dr. Patick. "I look forward to joining this stellar team of top notch scientists and am eager to help build on Genelabs' experience of discovering and developing important drugs for patients infected with hepatitis C virus."
About Genelabs Technologies
Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage vaccine candidate for hepatitis E virus partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus. For more information, please visit
  icon paper stack View Older Articles   Back to Top